Picture supply: Getty Photographs
Penny shares will be interesting investments due to their low share costs and potential for top returns. Nonetheless, investing in these speculative small-cap shares carries larger danger than shopping for equities listed on the FTSE 100 or FTSE 250 indexes.
Volatility is a key concern. Traders contemplating these high-risk funding propositions want the abdomen to endure large share value actions in pursuit of portfolio positive factors. Briefly, they’re not for the faint-hearted.
One firm that’s no stranger to volatility is Creo Medical (LSE:CREO). This AIM-listed healthcare gadget enterprise specialises in minimally invasive surgical endoscopy. Buying and selling at a 52-week low after a chronic shedding streak, is at present the right time to purchase this beaten-down penny inventory?
A falling share value
Creo Medical has seen its market cap evaporate in recent times as its share value has taken a battering. As we speak, the inventory market minnow’s valued for lower than £52m.
There are some worrying indicators on this penny inventory for potential buyers to observe carefully. The agency’s FY24 revenues failed to satisfy market expectations. The group complete of £30.4m represented a 1.3% decline in comparison with the prior yr’s determine of £30.8m. Frankly, it’s regarding to see the corporate going into reverse gear on such a vital metric.
Creo Medical has additionally but to show a revenue. The board expects FY25 will probably be one other loss-making yr. I’m fearful extra cash will must be raised earlier than the enterprise turns into a worthwhile enterprise, which might not be simple provided that it has traditionally skilled fundraising difficulties.
That stated, in February, the corporate secured £25m in web inflows from divesting a majority stake in its European consumables enterprise to a Chinese language medical gadget producer. Coupled with a £12.1m fairness elevate final yr, Creo Medical has some monetary headroom for the close to future not less than.
Restoration potential
On the intense facet, this month marked the business launch of a brand new product — the SpydrBlade Flex — within the UK and EU. This might present a much-needed enhance for the corporate’s backside line. The multi-modal endoscopic gadget has promising functions for minimally invasive remedy of colorectal most cancers.
As well as, the potential of Creo Medical’s core providing can’t be understated. Its flagship Speedboat product suite makes use of exceptional expertise. These tiny surgical devices provide surgeons a one-stop store to hold out incision, dissection, and coagulation procedures while not having to alter gadgets.
The market alternative is appreciable. Some analysts imagine the gastrointestinal endoscopic applied sciences market may very well be price between £2.32bn and £2.48bn. If Creo Medical can efficiently realise the business potential of its merchandise, the shares may in the end show to be a profitable funding at this early stage.
A penny inventory to think about?
Like all penny shares, Creo Medical faces important dangers. The truth that the shares have been as soon as altering arms for practically £2.30, in comparison with 12.5p at present, proves as a lot.
Nonetheless, the corporate’s danger/reward profile appears to be like engaging to me proper now at this low valuation. Enchancment will probably be wanted throughout a variety of core monetary yardsticks, however the agency’s distinctive patented applied sciences present important promise.
So, is Creo Medical a discount inventory? Fairly probably! Discount of the yr? That’s most likely a stretch. However for buyers with enough danger appetites, I believe this penny share deserves consideration.
